A review of the drug Depatux-M for glioblastoma
Original title: Depatuxizumab mafodotin in glioblastoma: A systematic review of efficacy, safety, pharmacokinetics and biomarker stratification.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This looks across many earlier studies rather than running a new one.
This is a summary of past studies, not a new result, and the drug is not approved or standard care.
The short version
Researchers pulled together past studies of a targeted drug for glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary, and it helped only a little.
What was studied. Researchers searched medical databases for studies on a drug called depatuxizumab mafodotin, or Depatux-M. They found 11 clinical studies with 1420 patients in total and looked at how well the drug worked, how safe it was, and who it might help.
What they found. The drug showed only modest activity against the tumors. Any benefit was seen mostly in people whose tumors had a specific change in a gene called EGFR. Eye problems were the most common side effect and happened in over 90% of patients. These eye problems could often be reversed and managed.
What this means, and what it doesn't
What it could mean: This drug is aimed at a subset of patients. About half of glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary cases have a change in EGFR. For that group, this kind of targeted treatment is worth continuing to study. The reviewers say the overall benefit so far is limited, and they call for future trials that test each patient's tumor genes to pick the right people.
What it doesn't mean: This is not a new result. It is a review that adds up studies that already happened. It does not mean this drug is available for you, and it is not a cure. The reviewers said its benefit is limited. Eye side effects were very common. Anything here is still a research question, not everyday care.
Source: PubMed, August 5, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.